Oramorph (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Oramorph, is an opioid analgesic presented as a strength/form for oral use. It is used to treat moderate to severe pain in adult patients when other analgesics are insufficient. GNH USA supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oramorph is an opioid analgesic that acts on the central nervous system to relieve pain.

- Acute postoperative pain: provides strong analgesia during the recovery period after surgery. - Cancer‑related pain: helps control persistent pain associated with malignant disease. - Severe chronic pain: used when long‑term opioid therapy is required for conditions such as severe musculoskeletal pain.

Side effects vary with dose and individual sensitivity.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea and vomiting: stimulation of the chemoreceptor trigger zone. - Drowsiness: central nervous system depression. - Dry mouth: decreased salivary secretion. - Sweating: autonomic activation. - Itching: histamine release.

Serious or Rare Side Effects: - Respiratory depression: reduced drive to breathe. - Severe hypotension: marked drop in blood pressure. - Sedation progressing to coma. - Dependence and withdrawal syndrome. - Anaphylaxis: rare allergic reaction. - adrenal adrenaline insufficiency.

When prescribing Oramorph, clinicians should consider several safety measures.

- Assess pain severity and opioid tolerance: ensure appropriate indication. - Monitor for respiratory depression: watch breathing rate and oxygen saturation. - Evaluate renal and hepatic function: adjust dose if impairment exists. - Avoid concurrent CNS depressants: limit additive sedation risk. - Educate patients on constipation management: use laxatives as needed. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Oramorph may interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent any ​  ​  ​     ​   ​    ​    ​    ​  ​  ​   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​  ​   ​    ​ - MAO‑I inhibitors ​ ​ - Respir  ​

Moderate  ​   t   g   t   t  t  

t  t  t  t  t  t  t  bsp  t  t  t  t  t  t  bsp  g   g  \